CSIR-CCMB Develops India-Specific Tool to Predict Sickle Cell Disease Severity | Explained
Doctors in India may soon be able to predict how severely Sickle Cell Anaemia (SCA) will affect patients with greater accuracy, thanks to a new India-specific disease severity scoring system developed by scientists at the CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB).
The newly developed tool is designed using clinical data from Indian children and addresses a long-standing challenge: existing international severity scoring systems often fail to accurately predict disease progression in Indian patients because of genetic, environmental and clinical differences.
The research marks an important step toward personalized treatment and improved disease management for one of India's most significant inherited blood disorders.
Key Highlights
|
What Is the New India-Specific Sickle Cell Severity Score?
Scientists at the CSIR-Centre for Cellular and Molecular Biology (CCMB) have developed a new clinical scoring system to predict how severe Sickle Cell Anaemia (SCA) is likely to become in Indian patients.
Unlike existing international scoring systems, which were largely developed using African and Western patient populations, the new model considers the unique clinical characteristics commonly observed among Indian patients.
The researchers created two new scoring models:
ISS1 (India-Specific Severity Score 1)
ISS2 (India-Specific Severity Score 2)
Both models significantly improve the accuracy of clinical assessments and could help doctors identify high-risk patients at an earlier stage.
Why Was a New Tool Needed?
Although Sickle Cell Anaemia is caused by a single genetic mutation, its severity varies widely among patients.
Some individuals experience relatively mild symptoms throughout life, while others suffer from:
Frequent hospitalisations
Severe anaemia
Painful crises
Organ damage
Life-threatening complications
Existing international scoring systems do not adequately reflect the disease pattern seen in Indian patients.
According to researchers, Indian patients generally have a milder clinical profile than many African populations because they often possess higher levels of fetal haemoglobin (HbF), which helps reduce disease severity.
However, nutritional deficiencies, infections and environmental stress can significantly worsen the condition.
What Is Sickle Cell Anaemia?
Sickle Cell Anaemia (SCA) is an inherited genetic blood disorder caused by a mutation in the beta-globin gene.
The mutation leads to the production of abnormal haemoglobin known as haemoglobin S, causing red blood cells to become rigid and sickle-shaped instead of flexible and round.
These abnormal cells block blood vessels and break down prematurely, resulting in:
Chronic anaemia
Severe pain episodes
Fatigue
Organ damage
Increased risk of infections
Stroke and other complications
India is among the countries with the highest burden of Sickle Cell Disease, particularly among tribal populations.
How Was the New Scoring System Developed?
The research team analysed medical records of 171 children aged up to 18 years receiving treatment at the Government Medical College and Hospital, Nagpur.
Two experienced paediatricians independently classified patients into:
Mild
Moderate
Severe
based on their overall clinical condition.
The researchers then compared these expert assessments with existing international scoring systems.
Why Did Existing International Scores Fall Short?
The widely used Paediatric Severity Score (PSS) correctly matched doctors' assessments in only about 67% of cases.
Researchers found that several clinical features common among Indian patients were not adequately represented in international models.
To address this, they incorporated four important indicators frequently observed in India:
Recurrent blood transfusions
Severe anaemia requiring hospitalisation
Acute febrile illnesses
Additional clinical indicators relevant to Indian patients
ISS1 and ISS2: What Makes Them Different?
ISS1 (India-Specific Severity Score)
The first model improved agreement with expert clinical assessments from 67% to nearly 83%.
ISS2 (India-Specific Severity Score)
The second version simplified the assessment further by replacing laboratory-based measurements with easily observable clinical signs.
ISS2 achieved an overall concordance of approximately 85%, while correctly identifying all patients with mild disease and improving diagnosis in moderate cases.
Because it relies less on laboratory investigations, ISS2 could be especially useful in resource-limited healthcare settings.
How Can the Tool Help Doctors?
The new scoring system could enable physicians to:
Identify high-risk patients earlier
Decide appropriate treatment more quickly
Determine the optimal use and dosage of hydroxyurea, the primary medicine used to manage Sickle Cell Disease
Reduce unnecessary laboratory investigations
Improve long-term disease monitoring
Early identification of severe cases can also help prevent complications through timely intervention.
Major Findings of the Study
Researchers observed that among Indian children with Sickle Cell Anaemia:
Painful vaso-occlusive crises were the most common complication.
Frequent blood transfusions were associated with severe disease.
Severe anaemia often required repeated hospitalisation.
Recurrent fever-related illnesses significantly contributed to disease severity.
These observations formed the basis of the India-specific scoring system.
Can the Tool Be Used Outside India?
According to the researchers, the new severity score could potentially benefit other low- and middle-income countries with similar genetic backgrounds, disease patterns and healthcare challenges.
However, they emphasised that larger validation studies across more diverse populations will be necessary before widespread adoption.
Why This Research Matters
India carries one of the world's largest burdens of Sickle Cell Disease, making early diagnosis and personalised treatment particularly important.
The development of a population-specific severity score represents a significant advancement toward precision medicine, ensuring that treatment decisions are based on the characteristics of Indian patients rather than international models.
The research also supports the broader objectives of the CSIR Sickle Cell Anaemia Mission, which aims to improve diagnosis, treatment and quality of life for patients across the country.
The India-specific Sickle Cell severity score developed by CSIR-CCMB marks a major milestone in improving care for patients living with Sickle Cell Anaemia. By accurately identifying disease severity using clinical features commonly seen in Indian patients, the tool could help doctors make quicker and more informed treatment decisions.
If validated in larger studies, ISS1 and ISS2 may become valuable clinical tools not only in India but also in other countries facing similar healthcare challenges.
Frequently Asked Questions (FAQs)
Q1. What is the new India-specific Sickle Cell severity score?
Answer. It is a clinical tool developed by CSIR-CCMB to predict disease severity in Indian patients with Sickle Cell Anaemia more accurately than existing international models.
Q2. Why was a new scoring system needed?
Answer. International scoring systems were developed using African and Western populations and do not accurately reflect the clinical characteristics of Indian patients.
Q3. What is Sickle Cell Anaemia?
Answer. Sickle Cell Anaemia is an inherited blood disorder caused by a mutation in the beta-globin gene that results in abnormal, sickle-shaped red blood cells.
Q4. What are ISS1 and ISS2?
Answer. ISS1 and ISS2 are two India-specific severity scoring models developed by CSIR-CCMB to improve diagnosis and treatment planning for Sickle Cell Disease.
Q5. How can the new tool benefit patients?
Answer. It can help doctors identify severe cases earlier, optimize hydroxyurea treatment, reduce unnecessary laboratory tests and improve overall disease management.
Comments